What is BI-RADS (Breast Imaging-Reporting and Data System)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

BI-RADS: Breast Imaging Reporting and Data System

BI-RADS is a standardized classification system developed by the American College of Radiology (ACR) that categorizes breast imaging findings into seven assessment categories (0-6) based on malignancy risk, with each category linked to specific management recommendations. 1, 2

Purpose and Structure

BI-RADS was created to reduce variability between radiologists and establish uniform reporting standards for mammography, ultrasound, and MRI. 1, 3 The system includes three key components:

  • Standardized lexicon with descriptive terms for breast abnormalities 4, 3
  • Assessment categories that predict likelihood of malignancy 1, 2
  • Management recommendations tied to each category 1, 2

The Seven Assessment Categories

Category 0: Incomplete Assessment

  • Additional imaging or prior mammograms needed for comparison 2
  • Typically used in screening situations requiring additional views or ultrasound 2

Category 1: Negative

  • No abnormalities detected 1, 2
  • Breasts are symmetric with no masses, architectural distortion, or suspicious calcifications 1, 2
  • Management: Resume routine annual screening 2

Category 2: Benign Findings

  • Negative mammogram with definitively benign findings 1, 2
  • Examples include calcifying fibroadenomas, oil cysts, lipomas, intramammary lymph nodes, vascular calcifications, implants, or surgical changes 1, 2
  • Management: Resume routine annual screening 2

Category 3: Probably Benign

  • Malignancy risk less than 2% 1, 2, 5
  • Requires short-interval follow-up to ensure stability 1, 2
  • Management: Diagnostic mammograms at 6 months, then every 6-12 months for 1-2 years 2
  • If stable or resolved, return to routine screening; if changes occur, proceed to biopsy 2

Category 4: Suspicious Abnormality

  • Wide range of malignancy probability, but not definitively malignant 1
  • Risk greater than Category 3 but less than Category 5 2
  • Management: Tissue diagnosis required using core needle biopsy (preferred) or needle localization excisional biopsy with specimen radiograph 1, 2

Category 5: Highly Suggestive of Malignancy

  • Malignancy probability ≥95% 2
  • Examples include spiculated masses or malignant-appearing pleomorphic calcifications 2
  • Management: Tissue diagnosis required using core needle biopsy (preferred) or needle localization excisional biopsy 1, 2

Category 6: Known Biopsy-Proven Malignancy

  • Added in the fourth edition for lesions confirmed malignant by biopsy but before definitive treatment 1, 2
  • Management: Follow breast cancer treatment guidelines 1, 2

Critical Clinical Principles

Assessment Based on Most Worrisome Finding

When multiple abnormalities are present, the overall BI-RADS category is determined by the most suspicious lesion. 1, 2

Cumulative Assessment with Multiple Modalities

When both mammography and ultrasound are performed, the BI-RADS category represents cumulative findings from both studies. 1, 2 The assessment can increase, decrease, or remain unchanged based on subsequent imaging. 1, 2

Pathology-Imaging Concordance is Mandatory

When biopsy is performed for Categories 4 or 5, concordance between pathology and imaging findings must be verified. 1, 2 For example, a negative fine needle aspiration with a spiculated Category 5 mass is discordant and unacceptable. 1 When discordance exists, repeat imaging and additional tissue sampling or surgical excision is required. 1, 2

Common Pitfalls to Avoid

Do not use Category 3 for classically benign findings - these should be Category 2. 5 Category 3 is reserved only when malignancy likelihood is truly less than 2%. 5

Do not skip biopsy for Categories 4 and 5 - tissue diagnosis is mandatory regardless of patient anxiety or preferences. 1

Do not ignore discordant pathology - when imaging suggests malignancy but biopsy shows benign findings, surgical excision is required if discordance persists. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

BIRADS Classification and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Breast imaging reporting and data system (BI-RADS).

Radiologic clinics of North America, 2002

Research

BIRADS classification in mammography.

European journal of radiology, 2007

Research

BI-RADS 3 for magnetic resonance imaging.

Magnetic resonance imaging clinics of North America, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.